Last 24 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '26 | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.45 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.52 | 1.45 | 17.45 | 1.58 | 1.25 | 1.77 | 1.70 | 1.34 | 1.16 | 13.13 | 1.69 | 44.97 | 18.84 | 323.25 | 7.87 | 371.70 | 28.67 | 32.35 | 13.17 | — | 52.36 |
| — | -18.1% | +925.8% | +18.1% | +7.7% | -86.6% | +0.5% | -97.0% | -93.8% | -95.9% | -78.5% | -87.9% | -34.3% | +899.2% | -40.2% | — | -45.2% | — | -87.7% | — | -22.7% | |
| P/B Ratio | 0.58 | 1.00 | 4.25 | 0.08 | 0.09 | 0.06 | 0.12 | 0.07 | 0.10 | 0.10 | 0.13 | 4.05 | 2.75 | 4.66 | 8.27 | 8.52 | 7.80 | 10.10 | 8.23 | 11.58 | 10.65 |
| — | +1448.5% | +3324.7% | +16.9% | -10.6% | -32.2% | -4.1% | -98.2% | -96.3% | -98.0% | -98.4% | -52.5% | -64.8% | -53.9% | +0.5% | -26.4% | -26.7% | -22.4% | -38.3% | -58.4% | -22.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q4 '26 | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.0% | 89.9% | -673.6% | -1802.8% | -704.7% | -1119.4% | 52.8% | 49.2% | 44.5% | -555.5% | 54.5% | 38.4% | 52.4% | -8714.9% | -61.5% | -6344.9% | -232.3% | -104.2% | -9.7% | — | -70.4% |
| — | +108.0% | -1375.2% | -3761.7% | -1683.1% | -101.5% | -3.1% | +28.4% | -15.1% | +93.6% | +188.6% | +100.6% | +122.6% | -8263.1% | -535.8% | — | -230.0% | -204.2% | +95.5% | — | +77.9% | |
| Operating Margin | -576.2% | -372.2% | -763.7% | -3938.3% | -1644.0% | -2572.9% | -2063.9% | -1199.4% | -1370.9% | -11419.7% | -908.8% | -661.2% | -569.8% | -10619.6% | -116.6% | -9240.7% | -416.3% | -263.2% | -125.1% | — | -258.0% |
| — | +85.5% | +63.0% | -228.4% | -19.9% | +77.5% | -127.1% | -81.4% | -140.6% | -7.5% | -679.7% | +92.8% | -36.9% | -3934.2% | +6.8% | — | -61.4% | -100.0% | +97.1% | — | +56.7% | |
| Net Margin | -544.8% | -328.8% | -744.4% | -2059.8% | -710.9% | -1241.3% | -1005.7% | -1058.9% | -1223.5% | -9356.5% | -781.3% | -609.5% | -896.9% | -6267.5% | -80.8% | -6914.7% | -380.4% | -321.9% | -102.1% | — | -255.5% |
| — | +73.5% | +26.0% | -94.5% | +41.9% | +86.7% | -28.7% | -73.7% | -36.4% | -49.3% | -867.2% | +91.2% | -135.8% | -1847.0% | +20.9% | — | -48.9% | -100.0% | +97.7% | — | +53.3% |
| Metric | TTM | Q4 '26 | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -75.6% | -43.5% | -37.0% | -24.7% | -12.4% | -14.1% | -16.8% | -18.1% | -24.2% | -15.7% | -17.9% | -15.0% | -42.2% | -24.5% | -22.7% | -33.4% | -25.9% | -27.8% | -16.1% | -10.6% | -12.2% |
| — | -209.2% | -119.7% | -36.7% | +48.8% | +10.3% | +5.7% | -20.4% | +42.8% | +35.9% | +21.3% | +55.0% | -63.1% | +11.7% | -40.8% | -213.6% | -112.1% | -75.7% | +90.6% | +90.2% | +56.6% | |
| ROA | -64.6% | -30.3% | -29.5% | -23.0% | -11.7% | -13.2% | -15.7% | -16.5% | -21.9% | -14.3% | -16.1% | -12.7% | -32.2% | -16.8% | -14.3% | -21.8% | -18.2% | -20.0% | -12.0% | -8.4% | -10.1% |
| — | -129.5% | -88.4% | -39.4% | +46.8% | +7.9% | +2.7% | -30.1% | +32.0% | +14.6% | -12.9% | +41.7% | -76.9% | +16.2% | -18.7% | -158.9% | -81.0% | -51.8% | +91.5% | +88.5% | +49.1% | |
| ROIC | -172.0% | -281.6% | -65.6% | -62.9% | -59.9% | -155.9% | -235.0% | -139.1% | -138.2% | -103.9% | -100.6% | -51.9% | -59.9% | -59.7% | -40.9% | -64.3% | -45.4% | -28.4% | -20.0% | -13.3% | -15.6% |
| — | -80.6% | +72.1% | +54.8% | +56.7% | -50.0% | -133.7% | -167.8% | -130.9% | -74.2% | -145.7% | +19.2% | -31.8% | -109.8% | -104.5% | -384.2% | -192.0% | -105.2% | +90.6% | +57.1% | +60.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '26 | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | 0.04 | 0.16 | 0.27 | 0.30 | 0.31 | 0.21 | 0.20 | 0.23 | 0.22 | 0.17 |
| — | +102.4% | -12.4% | +25.7% | -21.4% | -54.4% | -50.0% | -76.6% | -92.3% | -93.2% | -90.8% | -87.7% | -24.6% | +37.1% | +32.2% | +43.9% | +23.3% | +39.3% | +97.5% | +256.5% | +495.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.69 | 5.69 | 2.97 | 11.69 | 18.86 | 18.25 | 17.24 | 13.81 | 8.97 | 14.16 | 13.71 | 12.81 | 11.94 | 9.26 | 6.77 | 4.44 | 7.34 | 7.43 | 8.13 | 6.05 | 14.55 |
| — | -68.8% | -82.8% | -15.4% | +110.2% | +28.9% | +25.8% | +7.8% | -24.8% | +52.9% | +102.4% | +188.4% | +62.6% | +24.6% | -16.7% | -26.5% | -49.5% | -49.5% | -48.3% | +230.2% | +892.2% | |
| Quick Ratio | 5.69 | 5.69 | 2.97 | 11.69 | 18.86 | 18.25 | 17.24 | 13.81 | 8.97 | 14.16 | 13.71 | 12.81 | 11.94 | 9.26 | 6.77 | 4.44 | 7.21 | 7.43 | 8.13 | 5.80 | 14.55 |
| — | -68.8% | -82.8% | -15.4% | +110.2% | +28.9% | +25.8% | +7.8% | -24.8% | +52.9% | +102.4% | +188.4% | +65.7% | +24.6% | -16.7% | -23.5% | -50.5% | -48.1% | -48.3% | +216.9% | +972.2% | |
| Interest Coverage | -1235.43 | -802.43 | -2430.08 | — | — | -1182.83 | -2144.25 | -3696.02 | -1429.31 | -4171.37 | -2336.74 | -1444.68 | -3044.58 | -1841.39 | -1110.41 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IMMP stock.
Immutep Limited's current P/E is -0.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Immutep Limited's current operating margin is -576.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Immutep Limited's business trajectory between earnings reports.